Serological immunity to adenovirus serotype 5 is not associated with risk of HIV infection: a case-control study

被引：25

作者：

Curlin, Marcel E. ^{[1
,2
]}

Cassis-Ghavami, Farah ^{[2
]}

Magaret, Amalia S. ^{[2
,3
]}

Spies, Gregory A. ^{[2
]}

Duerr, Ann ^{[2
]}

Celum, Connie L. ^{[1
,4
,5
]}

Sanchez, Jorge L. ^{[6
]}

Margolick, Joseph B. ^{[7
]}

Detels, Roger ^{[8
]}

McElrath, M. Juliana ^{[1
,2
,5
]}

Corey, Lawrence ^{[1
,2
,3
]}

机构：

[1] Univ Washington, Dept Med, Seattle, WA 98195 USA

[2] Univ Washington, Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Inst, Seattle, WA 98195 USA

[3] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA

[4] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA

[5] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA

[6] Asociac Civil Impacta Salud & Educ, Lima, Peru

[7] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA

[8] Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA

来源：

AIDS | 2011年 / 25卷 / 02期

基金：

美国国家卫生研究院;

关键词：

acquisition risk; adenovirus; HIV; MSM; serology; vaccine; DOUBLE-BLIND; T-CELL; VACCINE; STEP; IMMUNIZATION; REPLICATION; VECTORS; COHORT; BACK; GENE;

D O I：

10.1097/QAD.0b013e328342115c

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

071005 [微生物学]; 100108 [医学免疫学];

摘要：

Background: Adenoviruses are among the most promising vectors for the development of an HIV vaccine. The results of the phase IIB study of the adenovirus serotype 5-based Merck Trivalent HIV vaccine have raised the concern that serological immunity to adenovirus serotype 5 (Ad5) could be linked to HIV acquisition risk in high-risk individuals. We examined the association between adenovirus serostatus and the rate of incident HIV infection in populations at elevated risk of HIV acquisition. Methods: We performed a nested case-control study of Ad5 serostatus among 299 HIV-infected and 590 matched HIV-uninfected persons participating in the Multicenter AIDS Cohort Study (MACS) and in HPTN 039, a study of herpes simplex virus 2 suppression among adults in the United States, South America, and Africa. Appropriate HIV cases and controls were identified in each cohort, and Ad5-neutralizing antibody titers were compared in these two groups. Results: In MACS and HPTN 039, the relative risks of incident HIV infection among Ad5-seropositive vs. Ad5-seronegative individuals were 1.1 (95% confidence interval 0.8-1.5, P = 0.57) and 1.0 (95% confidence interval 0.4-2.3, P = 0.99), respectively. HIV-1 acquisition rates did not vary significantly by Ad5-neutralizing antibody titer. Conclusion: The presence of Ad5-neutralizing antibodies is not linked to the risk of HIV acquisition among populations at elevated risk of HIV infection. (C) 2011 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins

引用

页码：153 / 158

页数：6

共 23 条

[1]

Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D [J].

Abbink, Peter ;

Lemckert, Angelique A. C. ;

Ewald, Bonnie A. ;

Lynch, Diana M. ;

Denholtz, Matthew ;

Smits, Shirley ;

Holterman, Lennart ;

Damen, Irma ;

Vogels, Ronald ;

Thorner, Anna R. ;

O'Brien, Kara L. ;

Carville, Angela ;

Mansfield, Keith G. ;

Goudsmit, Jaap ;

Havenga, Menzo J. E. ;

Barouch, Dan H. .

JOURNAL OF VIROLOGY, 2007, 81 (09) :4654-4663

[2]

Quantitative adenovirus neutralization assays based on the secreted alkaline phosphatase reporter gene:: Application in epidemiologic studies and in the design of adenovector vaccines [J].

Aste-Amézaga, M ;

Bett, AJ ;

Wang, FB ;

Casimiro, DR ;

Antonello, JM ;

Patel, DK ;

Dell, EC ;

Franlin, LL ;

Dougherty, NM ;

Bennett, PS ;

Perry, HC ;

Davies, ME ;

Shiver, JW ;

Keller, PM ;

Yeager, MD .

HUMAN GENE THERAPY, 2004, 15 (03) :293-304

[3]

First-in-human Phase 1 safety and immunigenicity of an adenovirus serotype 26 HIV-1 vaccine vector [J].

Baden, L. R. ;

Dolin, R. ;

O'Brien, K. L. ;

Abbink, P. ;

La Porte, A. ;

Seaman, M. S. ;

Choi, E. ;

Tucker, R. ;

Weitjens, M. ;

Pau, M. G. ;

Goudsmit, J. ;

Barouch, D. H. .

RETROVIROLOGY, 2009, 6

[4]

Buchbinder S, 2008, 15 C RETR OPP INF BO

[5]

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial [J].

Buchbinder, Susan P. ;

Mehrotra, Devon V. ;

Duerr, Ann ;

Fitzgerald, Daniel W. ;

Mogg, Robin ;

Li, David ;

Gilbert, Peter B. ;

Lama, Javier R. ;

Marmor, Michael ;

del Rio, Carlos ;

McElrath, M. Juliana ;

Casimiro, Danilo R. ;

Gottesdiener, Keith M. ;

Chodakewitz, Jeffrey A. ;

Corey, Lawrence ;

Robertson, Michael N. .

LANCET, 2008, 372 (9653) :1881-1893

[6]

Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial [J].

Celum, Connie ;

Wald, Anna ;

Hughes, James ;

Sanchez, Jorge ;

Reid, Stewart ;

Delany-Moretlwe, Sinead ;

Cowan, Frances ;

Casapia, Martin ;

Ortiz, Abner ;

Fuchs, Jonathan ;

Buchbinder, Susan ;

Koblin, Beryl ;

Zwerski, Sheryl ;

Rose, Scott ;

Wang, Jing ;

Corey, Lawrence .

LANCET, 2008, 371 (9630) :2109-2119

[7]

Post-Step modifications for research on HIV vaccines [J].

Corey, Lawrence ;

McElrath, M. Juliana ;

Kublin, James G. .

AIDS, 2009, 23 (01) :3-8

[8]

Perspective - HIV vaccine research: The way forward [J].

Fauci, Anthony S. ;

Johnston, Margaret I. ;

Dieffenbach, Carl W. ;

Burton, Dennis R. ;

Hammer, Scott M. ;

Hoxie, James A. ;

Martin, Malcolm ;

Overbaugh, Julie ;

Watkins, David I. ;

Mahmoud, Adel ;

Greene, Warner C. .

SCIENCE, 2008, 321 (5888) :530-532

[9]

Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice [J].

Hoelscher, MA ;

Garg, S ;

Bangari, DS ;

Belser, JA ;

Lu, XH ;

Stephenson, I ;

Bright, RA ;

Katz, JM ;

Mittal, SK ;

Sambhara, S .

LANCET, 2006, 367 (9509) :475-481

[10]

Baseline Ad5 serostatus does not predict Ad5 HIV vaccine-induced expansion of adenovirus-specific CD4+ T cells [J].

Hutnick, Natalie A. ;

Carnathan, Diane G. ;

Dubey, Sheri A. ;

Cox, Kara S. ;

Kierstead, Lisa ;

Ratcliffe, Sarah J. ;

Robertson, Michael N. ;

Casimiro, Danilo R. ;

Ertl, Hildegund C. J. ;

Betts, Michael R. .

NATURE MEDICINE, 2009, 15 (08) :876-878

← 1 2 3 →